title: [Hemodynamic effects of amrinone combined with dopamine in patients undergoing living renal transplantation].
abstract: Systemic hypertension is a constant feature of chronic renal failure, mediated by renin and exacerbated by salt and fluid loading. Vascular atherosclerosis appears to accelerate in patients on long-term dialysis. Therefore, it is important to control hypertension and keep appropriate renal blood flow during living renal transplantation surgery. Amrinone, a phosphodiesterase inhibitor, produces vasodilation in arterial smooth muscle as well as venodilation in the capacitance bed. By increasing myocardial contractility it increases inotropic effect. Amrinone has potent inodilator effects because of its dual mechanism of action. The current study is aimed to compare hemodynamic effects between amrinone (3-5 mg.kg-1.min-1) (AMR group, n = 4) and nitroglycerin (0.3-1.0 mg.kg-1.min-1) (NTG group, n = 5), combined with dopamine (3-5 mg.kg-1.min-1) in nine patients undergoing living renal transplantation. Increase in cardiac index in AMR group was significantly larger than that in NTG group. Values of systemic and pulmonary vascular resistance in AMR group were significantly smaller than those in NTG group. No significant difference was found in renal function in the post-operative period.
authors.affiliation: Department of Anesthesia, Osaka Prefectural General Hospital.
authors.forename: Y
authors.initials: Y
authors.lastname: Okuno
authors.forename: T
authors.initials: T
authors.lastname: Mashimo
authors.forename: M
authors.initials: M
authors.lastname: Takashina
authors.forename: S
authors.initials: S
authors.lastname: Hagihira
authors.forename: Y
authors.initials: Y
authors.lastname: Inagaki
authors.forename: T
authors.initials: T
authors.lastname: Mori
authors.forename: I
authors.initials: I
authors.lastname: Yoshiya
mesh_terms: D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000328:Adult; D000676:Amrinone / Q000494:pharmacology*; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D004298:Dopamine / Q000494:pharmacology*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000503:physiopathology / Q000601:surgery; D016030:Kidney Transplantation; D008297:Male; D005996:Nitroglycerin / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D014665:Vasodilator Agents; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D005996:Nitroglycerin; D000676:Amrinone; D004298:Dopamine